Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 2seventy bio, Inc. - Common Stock (NQ: TSVT ) 4.600 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about 2seventy bio, Inc. - Common Stock < Previous 1 2 3 4 5 6 Next > Benzinga Pro's Top 5 Stocks To Watch For Friday, May 12, 2023: CMCSA, KR, ON, TSVT, CMND May 12, 2023 Comcast (CMCSA) - The parent company of NBCUniversal. One of Friday's most-discussed stories stemmed from a tweet by Elon Musk he had found a new exec to file the chief exec role at Twitter. Via Benzinga 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 May 11, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio: Q1 Earnings Insights May 03, 2023 Via Benzinga 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress May 03, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio's Return On Capital Employed Overview March 20, 2023 Via Benzinga Wedbush Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know March 17, 2023 Via Benzinga Where 2seventy bio Stands With Analysts March 17, 2023 Via Benzinga SVB Leerink Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know January 10, 2023 Via Benzinga 2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting May 02, 2023 From 2seventy bio Via Business Wire 2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program May 01, 2023 From 2seventy bio Via Business Wire 2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023 April 28, 2023 From 2seventy bio, Inc. Via Business Wire Expert Ratings for 2seventy bio January 10, 2023 Via Benzinga Stocks That Hit 52-Week Lows On Monday April 24, 2023 On Monday, 147 stocks made new 52-week lows. Via Benzinga Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit April 19, 2023 The company could have the best-in-class CAR-T drug for multiple myeloma patients. Via Investor's Business Daily Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma April 17, 2023 From Bristol Myers Squibb Via Business Wire Stocks That Hit 52-Week Lows On Friday April 21, 2023 During Friday's session, 149 stocks hit new 52-week lows. Via Benzinga 2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress March 16, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors March 08, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference March 03, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio Announces Pricing of Upsized Public Offering of Common Stock February 28, 2023 From 2seventy bio, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session February 28, 2023 Via Benzinga 2seventy bio Announces Proposed Public Offering of Common Stock February 28, 2023 From 2seventy bio, Inc. Via Business Wire Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients February 10, 2023 Via Benzinga 2seventy bio to Participate in Upcoming Investor Conferences February 01, 2023 From 2seventy bio, Inc. Via Business Wire Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study February 10, 2023 From Bristol Myers Squibb Via Business Wire 2seventy bio Provides Company Outlook for 2023 January 09, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors January 06, 2023 From 2seventy bio, Inc. Via Business Wire Stocks That Hit 52-Week Lows On Thursday December 22, 2022 Thursday's session saw 329 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Tuesday December 20, 2022 On Tuesday, 298 companies achieved new lows for the year. Via Benzinga 4 Analysts Have This to Say About 2seventy bio November 08, 2022 Over the past 3 months, 4 analysts have published their opinion on 2seventy bio (NASDAQ:TSVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.